@misc{oai:repo.qst.go.jp:00065805,
 author = {李, 惠子 and 長谷川, 純崇 and 永津, 弘太郎 and 佐賀, 恒夫 and 李 惠子 and 長谷川 純崇 and 永津 弘太郎 and 佐賀 恒夫},
 month = {Nov},
 note = {【Objective】Astatine 211 (211At, T1/2=7.21h) is one of the attractive alpha emitter as it belongs to the same family as iodine, and the application into radioimmunotherapy (211At-RIT) is expected. We evaluated the biological effects of 211At-RIT both in vitro and in vivo.【Methods】211At was labeled with trastuzumab, anti-HER2 monoclonal antibody, using N-succinimidyl-3-(trimethylstannyl)benzoate. The in vitro cytotoxicity was evaluated by cell growth assay using a human metastatic gastric cancer cell line overexpressing HER2 protein. 211At-labeled trastuzumab, 0.5-2.5 MBq, was injected into mice bearing gastric cancer xenografts to determine the anti-tumor effect in vivo.【Results】211At-labeled trastuzumab showed significant cytotoxicity in vitro and suppressed tumor growth in vivo.【Conclusion】211At-RIT could be an effective treatment to HER2 overexpressing gastric cancer., 第55回日本核医学会学術総会},
 title = {α線放出核種211Atを用いた放射免疫療法},
 year = {2015}
}